ANTI CANCER

Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent

Next Investors Archived Nov 13, 2018

Imugene (ASX:IMU) is a clinical stage life sciences company on the cutting edge of this very field and is developing vaccines to boost and direct the immune system to target and attack cancer cells.

Race Oncology pens key deal to seek chemo drug Bisantrene licensing

Finfeed Archived Nov 01, 2018

Race Oncology (ASX:RAC) has come to agreement with Biosynergy to pursue licensing deals for chemotherapy drug, Bisantrene.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Next Investors Archived Oct 30, 2018

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Prescient onboards former Array Biopharma executive

Finfeed Archived Oct 29, 2018

Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.

Antisense rally prompts question: ‘Are ASX Biotechs back?’

Finfeed Archived Oct 17, 2018

The biotech sector was yesterday led by biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) which ended the day 217% higher.

Nanotechnology’s fantastic voyage

Finfeed Archived Oct 03, 2018

There are few companies dealing in nanotechnology in Australia, fewer still in the biotech space, which could make this a unique investment sector if investors are so inclined.

Can ASX biotech companies really grow wings?

Finfeed Archived Sep 07, 2018

The ethics of big pharma are debatable and deserve a long-form serious analysis, so let’s avoid the debate for now and look at the good work small biotech companies are doing.

Prescient Therapeutics improves manufacturing route for PTX-100

Finfeed Archived Sep 03, 2018

Prescient Therapeutics Ltd (ASX:PTX) has today advised it has identified an improved manufacturing route for PTX-100 for use in its upcoming pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial.

News from the world of biotech

Finfeed Archived Sep 03, 2018

The importance of biotech shouldn’t be underestimated, considering it can lead to tailor-made cures, eradication of diseases, better diagnostics and an overall healthier society.

Prescient Therapeutics expands PTX-200 oncology study

Finfeed Archived Aug 30, 2018

Clinical-stage oncology company, Prescient Therapeutics (ASX:PTX), this morning updated the market on its trial of PTX-200 with cytarabine in relapsed or refractory acute myeloid leukaemia (AML).

Prescient’s PTX 200 receives Notice of Allowance for US patent

Finfeed Archived Jul 26, 2018

Prescient Therapeutics Ltd (ASX:PTX) has received a Notice of Allowance for a new patent covering its lead clinical compound PTX-200 for the treatment of ovarian cancer in the United States.

Rhythm Biosciences’ ColoSTAT recognised in global markets

Finfeed Archived Jul 19, 2018

When Rhythm Biosciences (ASX:RHY) listed on the ASX in December 2017 its slogan was ‘taking Australian innovation to the world’ - its delivered in spades.

Merchant Group increases stake in Rhythm Biosciences

Finfeed Archived Jun 15, 2018

Medical diagnostics small cap Rhythm Biosciences Limited (ASX:RHY) has today announced that its new shareholder Merchant Group has increased its equity stake in the company from 5.02% to 7.01%.

Rhythm Biosciences scores leading biotech fund as new shareholder

Finfeed Archived Jun 12, 2018

Medical diagnostics innovator, Rhythm Biosciences (ASX:RHY), has welcomed leading biotech investor, Merchant Group, as a major new shareholder.

Bionomics announces Phase 2 clinical trial

Finfeed Archived May 23, 2018

Bionomics Limited (ASX:BNO) has today announced that a Phase 2 clinical trial for BNC210 has commenced in elderly patients with agitation in a hospital setting.

Rhythm Biosciences onboards two top health experts

Finfeed Archived May 22, 2018

Rhythm Biosciences Limited (ASX:RHY) has strengthened its management team by appointing two experienced health sector executives, including Glenn Gilbert as Chief Operating Officer.

BARD1 Life Sciences inks critical deal to develop autoantibody test

Finfeed Archived May 21, 2018

BARD1 Life Sciences (ASX:BD1) has penned an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test using ProcartaPlex® technology.

Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

Next Investors Archived May 21, 2018

BARD1 Life Sciences Limited (ASX:BD1) has both lung and ovarian cancer in its sights.

Anti Cancer